Neuropathology Overview

Principles

Definition

Neuropathology is the academic discipline dedicated to the study of diseases affecting the nervous system, particularly through the examination of structural and functional alterations in neural tissue. This field is essential for the diagnosis of neurological disorders, the elucidation of their underlying mechanisms, and the advancement of therapeutic approaches.

Ontological type

Core Methods

Disease Classification

Diagnostic Criteria

Key developments

Key Figures

Histopathology Taxonomy era

I. Klatzo [1] was a pivotal figure in the Histopathology Taxonomy era, with stints at the University of California, Berkeley [2] and the University of Gothenburg [3]. In the 1966 paper 'Selective Vulnerability of the Blood-Brain Barrier in Chemically Induced Lesions' [4], Klatzo illuminated how chemical insults yield selective damage to the CNS microvasculature, a finding that reinforced the era's morphology-first approach and its move toward lesion-specific histological mapping. These contributions helped standardize histopathology-driven diagnosis by linking tissue morphology to clinical syndromes and fostering clinicopathologic correlation across institutions, a hallmark of Klatzo's influence [1]. Together, his work underpinned the era's emphasis on integrated tissue-based methods and morphology-centered education, with continued impact on histochemistry and ultrastructural approaches that defined neuropathology rounds and curricula during the period [1].

Proteinopathy and Staging era

W. I. McDonald[1] was a key figure whose work in this era spanned institutions such as University College London[3] and the University of British Columbia[4]. His two important contributions were the New diagnostic criteria for multiple sclerosis: Guidelines for research protocols[7] and the Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis[8], which standardized diagnostic frameworks across research protocols and clinical practice and enabled cross-center comparability in this era. Heiko Braak[2] had affiliations with University of Pennsylvania[5] and Jacksonville College[6]. His staging framework is exemplified by Staging of brain pathology related to sporadic Parkinson’s disease[9] and Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry[10], which together established reproducible regional progression maps and anchored biomarker-driven research; Where Does Parkinson Disease Pathology Begin in the Brain?[11] offered a narrative on the earliest emergence of pathology in the brain during this era.

Propagation and Neuroimmune Modulation era

Jill S. Barnholtz‐Sloan [1] has been associated with the Institute of Cancer Research [3] and the University of California, San Francisco [4] during this era. Her key contributions in this era, based on the CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2006-2010 [5] and the CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2013–2017 [6], include compiling national brain tumor incidence and CNS tumor trends that provide essential baseline epidemiology informing diagnostic practice and research priorities. Quinn T. Ostrom [2] has been associated with the Institute of Cancer Research [3] and the University of California, San Francisco [4] during this era. His contributions through the CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2006-2010 [5] and the CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2013–2017 [6] provided standardized national brain tumor statistics that underpin resource allocation, diagnostic emphasis, and research agendas in the propagation and neuroimmune modulation era.